One has to wonder who checks the costing that Novartis uses to justify the price of its Kymriah Cancer Drug. What would Robert Koch, Louis Pasteur or Alexander Fleming make of this behaviour?
https://www.bloomberg.com//news/articles/2017-08-30/cancer-breakthrough-heralds-new-era-of-cures-costs-and-choices
A Brief History of Strategic Tariffs in the U.S.
-
A May 29 article in the IMF’s *F&D Magazine* argues in favor of using U.S.
tariffs as a policy tool. It begins by questioning the argument for free
trade...
1 day ago
No comments:
Post a Comment